Wall Street brokerages predict that Miragen Therapeutics Inc (NASDAQ:MGEN) will report $970,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Miragen Therapeutics’ earnings. The highest sales estimate is $1.50 million and the lowest is $700,000.00. Miragen Therapeutics posted sales of $480,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 102.1%. The firm is scheduled to issue its next earnings report on Wednesday, March 11th.
According to Zacks, analysts expect that Miragen Therapeutics will report full-year sales of $4.32 million for the current year, with estimates ranging from $3.60 million to $5.10 million. For the next year, analysts expect that the company will post sales of $3.27 million, with estimates ranging from $1.00 million to $6.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Miragen Therapeutics.
Miragen Therapeutics (NASDAQ:MGEN) last issued its earnings results on Thursday, November 7th. The medical research company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.67 million. Miragen Therapeutics had a negative net margin of 1,037.02% and a negative return on equity of 113.02%.
Shares of MGEN traded down $0.05 on Friday, reaching $0.69. The stock had a trading volume of 249,855 shares, compared to its average volume of 223,709. Miragen Therapeutics has a twelve month low of $0.57 and a twelve month high of $4.96. The firm has a market capitalization of $25.43 million, a PE ratio of -0.62 and a beta of 1.47. The firm has a 50-day moving average of $0.74 and a 200 day moving average of $1.47. The company has a quick ratio of 3.68, a current ratio of 3.68 and a debt-to-equity ratio of 0.23.
Hedge funds have recently added to or reduced their stakes in the company. A.R.T. Advisors LLC acquired a new position in shares of Miragen Therapeutics in the 2nd quarter valued at $28,000. Citadel Advisors LLC acquired a new position in Miragen Therapeutics in the second quarter valued at $57,000. Invesco Ltd. acquired a new position in Miragen Therapeutics in the second quarter valued at $71,000. Jane Street Group LLC purchased a new stake in Miragen Therapeutics during the second quarter valued at about $159,000. Finally, Paloma Partners Management Co purchased a new stake in Miragen Therapeutics during the second quarter valued at about $239,000. Institutional investors and hedge funds own 34.20% of the company’s stock.
About Miragen Therapeutics
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Featured Article: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.